147 related articles for article (PubMed ID: 8697641)
1. Tyrosinase as an autoantigen in patients with vitiligo.
Baharav E; Merimski O; Shoenfeld Y; Zigelman R; Gilbrud B; Yecheskel G; Youinou P; Fishman P
Clin Exp Immunol; 1996 Jul; 105(1):84-8. PubMed ID: 8697641
[TBL] [Abstract][Full Text] [Related]
2. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2).
Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
Clin Exp Immunol; 1997 Sep; 109(3):495-500. PubMed ID: 9328128
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
Fishman P; Merimski O; Baharav E; Shoenfeld Y
Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
[TBL] [Abstract][Full Text] [Related]
4. The role of tyrosinase in autoimmune vitiligo.
Song YH; Connor E; Li Y; Zorovich B; Balducci P; Maclaren N
Lancet; 1994 Oct; 344(8929):1049-52. PubMed ID: 7934446
[TBL] [Abstract][Full Text] [Related]
5. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
6. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay.
Kemp EH; Gawkrodger DJ; MacNeil S; Watson PF; Weetman AP
J Invest Dermatol; 1997 Jul; 109(1):69-73. PubMed ID: 9204957
[TBL] [Abstract][Full Text] [Related]
7. Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma: role of sequence similarity and HLA-DR1 affinity.
Lucchese A; Willers J; Mittelman A; Kanduc D; Dummer R
J Immunol; 2005 Nov; 175(10):7009-20. PubMed ID: 16272362
[TBL] [Abstract][Full Text] [Related]
8. Oxidized tyrosinase: A possible antigenic stimulus for non-segmental vitiligo autoantibodies.
Al-Shobaili HA; Rasheed Z
J Dermatol Sci; 2015 Sep; 79(3):203-13. PubMed ID: 26137927
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to human melanocyte-specific protein pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA).
Kemp EH; Gawkrodger DJ; Watson PF; Weetman AP
Clin Exp Immunol; 1998 Dec; 114(3):333-8. PubMed ID: 9844040
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo antibodies are not directed to tyrosinase.
Xie Z; Chen D; Jiao D; Bystryn JC
Arch Dermatol; 1999 Apr; 135(4):417-22. PubMed ID: 10206048
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay.
Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP
Br J Dermatol; 1998 Nov; 139(5):798-805. PubMed ID: 9892944
[TBL] [Abstract][Full Text] [Related]
12. Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo.
Kemp EH; Waterman EA; Gawkrodger DJ; Watson PF; Weetman AP
J Invest Dermatol; 1999 Aug; 113(2):267-71. PubMed ID: 10469315
[TBL] [Abstract][Full Text] [Related]
13. Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.
Dorđić M; Matić IZ; Filipović-Lješković I; Džodić R; Sašić M; Erić-Nikolić A; Vuletić A; Kolundžija B; Damjanović A; Grozdanić N; Nikolić S; Pralica J; Dobrosavljević D; Rašković S; Andrejević S; Juranić Z
BMC Complement Altern Med; 2012 Jul; 12():109. PubMed ID: 22834951
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
Zehtab T; Yazdanparast R; Rafieii S
Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo.
Kemp EH; Emhemad S; Akhtar S; Watson PF; Gawkrodger DJ; Weetman AP
Exp Dermatol; 2011 Jan; 20(1):35-40. PubMed ID: 21158937
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum anti-melanocyte antibodies and identification of related antigens in patients with vitiligo.
Zhu MC; Liu CG; Wang DX; Zhan Z
Genet Mol Res; 2015 Dec; 14(4):16060-73. PubMed ID: 26662399
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.
Merimsky O; Shoenfeld Y; Fishman P
Clin Rev Allergy Immunol; 1998; 16(3):227-36. PubMed ID: 9773250
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
19. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.
Kemp EH; Waterman EA; Hawes BE; O'Neill K; Gottumukkala RV; Gawkrodger DJ; Weetman AP; Watson PF
J Clin Invest; 2002 Apr; 109(7):923-30. PubMed ID: 11927619
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune response against tyrosinase induces depigmentation in C57BL/6 black mice.
Al Robaee AA; Alzolibani AA; Rasheed Z
Autoimmunity; 2020 Dec; 53(8):459-466. PubMed ID: 33084421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
